 Boston Scientific Corp. BSX, -0.11 reported Wednesday second-quarter profit and sales that topped expectations, but trimmed its full-year outlook, saying it maintained strong market positions amid continued macroeconomic challenges. The medical devices companys stock was still inactive in premarket trading. 